529 related articles for article (PubMed ID: 16498254)
1. Inflammatory bowel disease: current therapeutic options.
Domènech E
Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
[TBL] [Abstract][Full Text] [Related]
2. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
3. Optimizing therapy for inflammatory bowel disease.
Robinson M
Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
[TBL] [Abstract][Full Text] [Related]
4. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
5. The state of the art in the management of inflammatory bowel disease.
Hanauer SB; Present DH
Rev Gastroenterol Disord; 2003; 3(2):81-92. PubMed ID: 12776005
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
[TBL] [Abstract][Full Text] [Related]
7. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
8. [Classical medications in the treatment of inflammatory bowel diseases].
Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
10. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
Lakatos L; Lakatos PL
Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine.
Wahed M; Louis-Auguste JR; Baxter LM; Limdi JK; McCartney SA; Lindsay JO; Bloom SL
Aliment Pharmacol Ther; 2009 Sep; 30(6):614-20. PubMed ID: 19552632
[TBL] [Abstract][Full Text] [Related]
12. [Treatment strategies for inflammatory bowel disease].
Lémann M; Allez M
Rev Prat; 2005 May; 55(9):984-92. PubMed ID: 16052969
[TBL] [Abstract][Full Text] [Related]
13. [Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH].
Dejaco C; Haas T; Kirchgatterer A; Miehsler W; Wenzl H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W; Tilg H
Z Gastroenterol; 2006 Jun; 44(6):525-38; discussion 539. PubMed ID: 16773519
[TBL] [Abstract][Full Text] [Related]
14. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.
Panaccione R; Rutgeerts P; Sandborn WJ; Feagan B; Schreiber S; Ghosh S
Aliment Pharmacol Ther; 2008 Sep; 28(6):674-88. PubMed ID: 18532990
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of chronic inflammatory bowel diseases].
Lémann M
Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
[TBL] [Abstract][Full Text] [Related]
16. [Optimizing effect of infliximab upon inflammatory bowel disease].
Li SR; Sheng JQ; Li SJ; Zhao XJ
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacotherapy of inflammatory bowel disease].
Jojić N
Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
19. [Cyclosporine in inflammatory bowel disease].
Colomina Avilés J; Pascual Pérez R; Ortuño Cortés J; García García A; Del Pino Cuadrado J
An Med Interna; 1998 Apr; 15(4):214-8. PubMed ID: 9608068
[TBL] [Abstract][Full Text] [Related]
20. General principles of medical therapy of inflammatory bowel disease.
Friedman S
Gastroenterol Clin North Am; 2004 Jun; 33(2):191-208, viii. PubMed ID: 15177534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
